|
|
|
|
|
|
|
SIZE:
|
|
|
|
GENERIC NAME:
|
|
|
|
MANUFACTURER:
|
|
|
|
UNIT:
|
|
|
|
ADMINISTRATION ROUTE:
|
|
|
|
FDA PREGNANCY GROUP:
|
|
B
|
|
INDICATIONS:
|
|
Tinea corporis |
|
Tinea cruris |
|
Tinea pedis |
|
Tinea unguium |
|
Tinea versicolor |
| |
|
|
SIDE EFFECTS:
|
|
Dryness, redness, itching, burning, peeling, rash, stinging, tingling, or other signs of skin irritation that were not present before use of this medicine |
|
|
ABSOLUTE
CONTRAINDICATIONS :
|
|
|
|
RELATIVE
CONTRAINDICATIONS : |
|
|
|
ADULT DOSE:
|
|
Tinea corporis or
Tinea cruris-
Topical, to the skin and surrounding areas, once a day for one week. Treatment should be continued for at least one week even though symptoms of the disease may have improved.
Tinea pedis or
Tinea versicolor-
Topical, to the skin and surrounding areas, two times a day for one week. Treatment should be continued for at least one week even though symptoms of the disease may have improved. |
|
MAXIMUM ADULT DOSE:
|
|
|
|
PEDIATRIC DOSE:
|
|
Tinea corporis or
Tinea cruris or
Tinea pedis or
Tinea versicolor-
Safety and efficacy have not been established for these indications. |
|
MAXIMUM PEDIATRIC
DOSE:
|
|
|
|
ELDERLY DOSE:
|
|
|
|
|
|
|
|